BACKGROUND: Failing human myocardium is characterized by abnormal relaxation, a deficient sarcoplasmic reticulum (SR) Ca(2+) uptake, and a negative frequency response, which have all been related to a deficiency in the SR Ca(2+) ATPase (SERCA2a) pump. METHODS AND RESULTS: To test the hypothesis that an increase in SERCA2a could improve contractile function in cardiomyocytes, we overexpressed SERCA2a in human ventricular myocytes from 10 patients with end-stage heart failure and examined intracellular Ca(2+) handling and contractile function. Overexpression of SERCA2a resulted in an increase in both protein expression and pump activity and induced a faster contraction velocity (26.7+/-6.7% versus 16.6+/-2.7% shortening per second, P<0.005) and enhanced relaxation velocity (32. 0+/-10.1% versus 15.1+/-2.4%, P<0.005). Diastolic Ca(2+) was decreased in failing cardiomyocytes overexpressing SERCA2a (270+/-26 versus 347+/-30 nmol/L, P<0.005), whereas systolic Ca(2+) was increased (601+/-38 versus 508+/-25 nmol/L, P<0.05). In addition, the frequency response was normalized in cardiomyocytes overexpressing SERCA2a. CONCLUSIONS: These results support the premise that gene-based therapies and targeting of specific pathways in human heart failure may offer a new modality for the treatment of this disease.
BACKGROUND: Failing human myocardium is characterized by abnormal relaxation, a deficient sarcoplasmic reticulum (SR) Ca(2+) uptake, and a negative frequency response, which have all been related to a deficiency in the SR Ca(2+) ATPase (SERCA2a) pump. METHODS AND RESULTS: To test the hypothesis that an increase in SERCA2a could improve contractile function in cardiomyocytes, we overexpressed SERCA2a in human ventricular myocytes from 10 patients with end-stage heart failure and examined intracellular Ca(2+) handling and contractile function. Overexpression of SERCA2a resulted in an increase in both protein expression and pump activity and induced a faster contraction velocity (26.7+/-6.7% versus 16.6+/-2.7% shortening per second, P<0.005) and enhanced relaxation velocity (32. 0+/-10.1% versus 15.1+/-2.4%, P<0.005). Diastolic Ca(2+) was decreased in failing cardiomyocytes overexpressing SERCA2a (270+/-26 versus 347+/-30 nmol/L, P<0.005), whereas systolic Ca(2+) was increased (601+/-38 versus 508+/-25 nmol/L, P<0.05). In addition, the frequency response was normalized in cardiomyocytes overexpressing SERCA2a. CONCLUSIONS: These results support the premise that gene-based therapies and targeting of specific pathways in humanheart failure may offer a new modality for the treatment of this disease.
Authors: H He; F J Giordano; R Hilal-Dandan; D J Choi; H A Rockman; P M McDonough; W F Bluhm; M Meyer; M R Sayen; E Swanson; W H Dillmann Journal: J Clin Invest Date: 1997-07-15 Impact factor: 14.808
Authors: M Meyer; W Schillinger; B Pieske; C Holubarsch; C Heilmann; H Posival; G Kuwajima; K Mikoshiba; H Just; G Hasenfuss Journal: Circulation Date: 1995-08-15 Impact factor: 29.690
Authors: G Hasenfuss; H Reinecke; R Studer; M Meyer; B Pieske; J Holtz; C Holubarsch; H Posival; H Just; H Drexler Journal: Circ Res Date: 1994-09 Impact factor: 17.367
Authors: Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias Journal: Mol Cell Biol Date: 2002-06 Impact factor: 4.272
Authors: Lahouaria Hadri; Razmig G Kratlian; Ludovic Benard; Bradley A Maron; Peter Dorfmüller; Dennis Ladage; Christophe Guignabert; Kiyotake Ishikawa; Jaume Aguero; Borja Ibanez; Irene C Turnbull; Erik Kohlbrenner; Lifan Liang; Krisztina Zsebo; Marc Humbert; Jean-Sébastien Hulot; Yoshiaki Kawase; Roger J Hajjar; Jane A Leopold Journal: Circulation Date: 2013-06-26 Impact factor: 29.690
Authors: J Michael O'Donnell; Aaron Fields; Xianyao Xu; Shamim A K Chowdhury; David L Geenen; Jian Bi Journal: Am J Physiol Heart Circ Physiol Date: 2008-10-24 Impact factor: 4.733